StemCell Institute (TSE:7096) Stock Based Compensation: 円0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:7096 StemCell Institute TSE:7096
69 GF Score
Price 円701.00
GF Value 円1,823.27
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is StemCell Institute Stock Based Compensation?

StemCell Institute TSE:7096 -1.68% 69 Stock Based Compensation is 円0 Mil as of Mar. 2026. GuruFocus rates TSE:7096 with a GF Score™ of 69/100 and a GF Value™ of 円1,823.27 (Possible Value Trap). The stock has 5 warning signs investors should review.

StemCell Institute's Stock Based Compensation for the six months ended in Mar. 2026 was 円0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was 円0 Mil.

StemCell Institute Stock Based Compensation Related Terms

StemCell Institute Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for StemCell Institute's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StemCell Institute Stock Based Compensation Chart

StemCell Institute Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

StemCell Institute Semi-Annual Data
Mar18 Mar19 Mar20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:7096
69GF Score
StemCell Institute TSE:7096
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

StemCell Institute Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円0 Mil.

What does a Stock Based Compensation of 円0 Mil mean?
StemCell Institute (TSE:7096) has a Stock Based Compensation of 円0 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for StemCell Institute and its competitors.
Is StemCell Institute's Stock Based Compensation too high?
StemCell Institute's current Stock Based Compensation is 円0 Mil. Overall, StemCell Institute has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does StemCell Institute's Stock Based Compensation compare to VRTX and REGN?
StemCell Institute's Stock Based Compensation of 円0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for StemCell Institute and its competitors. StemCell Institute's current Stock Based Compensation is 円0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCell Institute stock overvalued right now?
Based on GuruFocus' analysis, StemCell Institute (TSE:7096) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,823.27, compared to a current price of 円701.00 — trading 61.6% below its estimated fair value. The current Stock Based Compensation is 円0 Mil. StemCell Institute's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For StemCell Institute (TSE:7096), the current Stock Based Compensation is 円0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is StemCell Institute (TSE:7096) Overvalued in 2026?

Based on GuruFocus' analysis, StemCell Institute stock appears to be undervalued. The current stock price of 円701.00 is trading 61.6% below its estimated GF Value™ of 円1,823.27. GuruFocus considers StemCell Institute to be Possible Value Trap.

Key valuation signals for TSE:7096:

  • Stock Based Compensation: 円0 Mil
  • GF Value™: 円1,823.27 vs. price of 円701.00 (61.6% below fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the TSE:7096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

StemCell Institute Business Description

Address 1-21-19 Toranomon, Minato-ku, Tokyo, JPN, 105-0001
StemCell Institute is engaged in the Cell bank business that separates and stores cord blood for regenerative medicine. Cord blood is the baby's blood contained in the umbilical cord and placenta that connects the mother and baby. In its umbilical cord blood storage business, upon receiving notification from customers who have contracted, umbilical cord blood collected at obstetric facilities throughout Japan is collected, transported to the company's cell processing center within 48 hours, and it provides a service to store cells at ultra-low temperature after separating cells from blood. The Company operates in a single segment, the cell bank business sales consist of three components: technical fees, storage fees, and other fees.
69GF Score

Get the complete analysis for TSE:7096

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円701.00
Price
円1,823.27
GF Value